In Flemingsberg, we cure diseases that were previously considered incurable

Earlier this year we hosted the most meaningful ATMP event of the spring, in collaboration with Miltenyi Biotec and the Karolinska ATMP Center, Karolinska University Hospital and Karolinska Institutet. We gathered over 120 participants, all sharing a vision of creating momentum to accelerate access to ATMPs in the Nordics.

”It’s fantastic, it’s a great opportunity to learn more about what’s going on at Karolinska and for the whole ATMP environment. From the Pre GMP to the manufacturing, to then the clinical trials that they offer here, and I think that’s one of the things that are really unique about the whole Flemingsberg ATMP ecosystem” – Jonathan Clarke, Development Manager at SmartCella.

During the event we launched ATMP Flemingsberg, a platform that encapsulates all the expertise within ATMP in Flemingsberg, from research to clinical implementation.

”We have everything in Flemingsberg and you can see that because they come here from Uppsala and other parts of the world to manufacture their products and do their treatments here” – Ewa Ellis, ATMP coordinator at Karolinska University Hospital.

The seminar shed light on Pre-GMP and GMP, as well as how to advance one’s process to the next level and how Vecura can assist in scaling up. Additionally, Stefan Mielke, an expert in the field, discussed equal access and emphasized the importance of collaborative efforts to make therapies more accessible to patients. Di Yu from Elicera Therapeutics also shared their journey, which began at Vecura in Flemingsberg.

“Clinical trials are very important because they bring innovation to our patients. For those of you who don’t know what CAR-T cells are, they are like glasses for T-cells, so that they can see tumor cells.” – Stephan Mielke, Professor and Scientific Director of the Cancer Center.

Watch our film below, summarizing our successful event. Together, we can accelerate access to ATMPs in the Nordics.

Visit atmpflemingsberg.se

*ATMP (Advanced Therapy Medicinal Products) också kallade Avancerade terapiläkemedel är baserade på celler, vävnader eller gener och delas in i tre huvudkategorier: somatiska cellterapier, genterapier och vävnadstekniska produkter.

Exploring a Snow-Covered Skellefteå: A Journey into a growing city

In late November of this year, Stiftelsen Flemingsberg Science visited Skellefteå alongside Karolina Krön and Pia Forsberg from Huddinge Municipality for a two-day exploration. The days not only brought snow but also provided an opportunity to gain insights into Skellefteå's development since the establishment of Northvolt and its impacts on the city.

A Shared Value Proposition for Future Flemingsberg

We are creating a shared value proposition for Flemingsberg in collaboration with Huddinge and Botkyrka municipalities, supported by Fabege, Hemsö, and the Clara Foundation. This joint initiative has been developed in consultation with the communication agency Gullers Grupp and is a result of the initiative from the Flemingsberg Science Foundation.

Innovation, collaboration, and culture converge in Flemingsberg

This year's Innovation and Collaboration Days in Flemingsberg focused on how innovation, research, and educational collaboration can contribute to a sustainable society, as well as the need for cultural industries in a growing neighborhood.

Previous 353637 Next